TrialAmerican journal of hematology2021

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Shambavi Richard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.